{
  "id": 18749750,
  "title": "Choosing Healthcare ETFs: Why IHE Outperforms IBB for Many Investors",
  "url": "https://urgent.news/2026/11/07/choosing-healthcare-etfs-why-ihe-outperforms-ibb-for-many-investors-18749750",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-11-07T16:35:01.000Z",
  "source": {
    "name": "Nasdaq Markets",
    "slug": "nasdaq-markets",
    "url": "https://www.nasdaq.com/articles/choosing-healthcare-etfs-why-ihe-outperforms-ibb-many-investors"
  },
  "original_language": "en",
  "account": null,
  "summary": "The iShares U.S. Pharmaceuticals ETF (IHE) and the iShares Biotechnology ETF (IBB) target different segments of the domestic healthcare market. According to Motley Fool, IHE focuses on established drugmakers with recurring revenue, while IBB provides broader exposure to higher-volatility biotechnology research and development companies, including many smaller research-driven firms. Nasdaq Markets notes that IHE offers a lower expense ratio and a significantly higher dividend yield than IBB.\n\nMotley Fool reports that IHE is the more affordable option with a 0.37% expense ratio, compared to 0.44% for IBB. Additionally, IHE provides a 1.4% dividend yield, which is higher than the 0.2% yield offered by IBB.",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 2,
    "also_reported_by": [
      {
        "outlet": "Motley Fool",
        "title": "Choosing Healthcare ETFs: Why IHE Outperforms IBB for Many Investors",
        "url": "https://urgent.news/2026/11/07/choosing-healthcare-etfs-why-ihe-outperforms-ibb-for-many-investors",
        "published": "2026-11-07T16:15:01.000Z"
      }
    ]
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}